Compare INLX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | AEON |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 25.8M |
| IPO Year | 2013 | N/A |
| Metric | INLX | AEON |
|---|---|---|
| Price | $6.70 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 1.7K | ★ 69.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,336.00 | N/A |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.25 | $0.53 |
| 52 Week High | $14.57 | $1.45 |
| Indicator | INLX | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 32.80 |
| Support Level | N/A | $0.70 |
| Resistance Level | $7.87 | $0.83 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 29.22 | 8.14 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.